BioLineRx is a biopharmaceutical development company building a portfolio of products for either unmet medical needs or to replace currently available therapies with significant advantages. The company currently has six clinical stage candidates along with nine products in various preclinical development stages for a number of indications.
The company announced today that its orally available treatment for celiac disease, BL-7010, was found to be safe and well-tolerated and did not cause any adverse effects (even at high doses) in preclinical studies conducted to date. Additional studies showed that BL-7010 is specific to gliadins, the immunogenic peptides present in gluten that causes celiac disease and does not interact with non-related enzymes or vitamins in the digestive tract.
Additional efficacy studies of BL-7010 indicate it reduces digestion of wheat gluten, thereby decreasing its toxicity. BL-7010 also attenuates the immune response to gluten in rodents and prevents gluten-induced pathological damage to the small intestine. BL-7010 is not absorbed systemically which indicates its safety as a gluten neutralizing substance.
Professor Elena Verdu, who presented the data on BL-7010 to Better Life for Coeliacs 2012 Congress in Helsinki, said "BL-7010 may therefore be an effective adjuvant therapy [in addition to gluten-free diets] that will improve the quality of life for people with celiac disease throughout the world."
If the findings are validated, it would certainly present an opportunity for BioLineRX to have a very successful treatment on its hands. For further information on BioLineRX, BL-7010, and the company's entire portfolio of drug candidates, please visit the company's website at biolinerx.com.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net